CHRS

Coherus Oncology Stock Analysis

AI Rating

Great
  • Quality6/10
  • Growth↑ 9/10
  • Value↑ 5/10
Coherus Oncology sales and earnings growth
CHRS Growth
Great
  • Revenue Y/Y↑ 14.43%
  • EPS Y/Y↑ 245.13%
  • FCF Y/Y↓ -34214.60%
Coherus Oncology gross and profit margin trends
CHRS Profitability
Great
  • Gross margin ↑ 68.10%
  • EPS margin↑ 397.30%
  • ROIC 5Y↑ 801.53%
Coherus Oncology net debt vs free cash flow
CHRS Risk
Great
  • Debt / Equity↓ 0.5
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 21.6

Coherus Oncology stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks